Celecoxib
Colorectal Cancer
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07154316CT.gov Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT06903858CT.gov Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT05933980CT.gov Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05281276CT.gov Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | — | Terminated | — | — | — |
NCT05327751CT.gov Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT03926338CT.gov Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer | — | Recruiting | — | — | — |
NCT03638297CT.gov PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | — | Unknown | — | — | — |
NCT03645187CT.gov Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03403634CT.gov Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT02615574CT.gov A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
Show 21 more trialsShow fewer
NCT02280694CT.gov Low Dose Metronomic Poly-chemotherapy for Metastatic CRC | — | Completed | — | — | — |
NCT01545141CT.gov Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | — | Terminated | — | — | — |
NCT01284504CT.gov Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer | — | Terminated | — | — | — |
NCT01150045CT.gov Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | — | Completed | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT00466505CT.gov Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00084721CT.gov Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00081224CT.gov Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | — | Terminated | — | — | — |
NCT00159484CT.gov Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00087256CT.gov Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer | — | Terminated | — | — | — |
NCT00085163CT.gov Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon | — | Completed | — | — | — |
NCT00072553CT.gov Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00230399CT.gov Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00064181CT.gov Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00043043CT.gov Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia | — | Completed | — | — | — |
NCT00685568CT.gov Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis | — | Completed | — | — | — |
NCT00608595CT.gov Celecoxib in Treating Patients With Early-Stage Rectal Cancer | — | Terminated | — | — | — |
NCT00336960CT.gov Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery | — | Completed | — | — | — |
NCT00258232CT.gov Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00033371CT.gov Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis | — | Completed | — | — | — |
NCT00473980CT.gov Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Fudan University | Approved | BB · 64 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Celecoxib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/celecoxib-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →